Mifepristone
Korlym, Mifeprex, Mifepristone (mifepristone) is a small molecule pharmaceutical. Mifepristone was first approved as Mifeprex on 2000-09-28. It is used to treat brain neoplasms, ectopic pregnancy, hyperglycemia, and meningeal neoplasms in the USA. The pharmaceutical is active against glucocorticoid receptor and progesterone receptor. In addition, it is known to target androgen receptor and nuclear receptor subfamily 1 group I member 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Korlym, Mifeprex, Mifepristone
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Mifepristone
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| KORLYM | Corcept Therapeutics | N-202107 RX | 2012-02-17 | 1 products, RLD, RS |
| MIFEPREX | Danco Laboratories | N-020687 RX | 2000-09-28 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| korlym | New Drug Application | 2025-01-21 |
| mifeprex | New Drug Application | 2025-03-12 |
| mifepristone | New Drug Application | 2025-01-28 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| brain neoplasms | EFO_0003833 | D001932 | C71 |
| meningeal neoplasms | EFO_0003851 | D008577 | C70 |
| hyperglycemia | — | D006943 | R73.9 |
| ectopic pregnancy | — | D011271 | O00 |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Mifepristone, Korlym, Corcept Therap | |||
| 10231983 | 2038-08-22 | U-1643 | |
| 10314850 | 2038-08-22 | U-1643 | |
| 10780097 | 2038-08-22 | U-1643 | |
| 10195214 | 2037-06-19 | U-1643 | |
| 10842800 | 2037-06-19 | U-1643 | |
| 10151763 | 2037-01-18 | U-1643 | |
| 9829495 | 2036-08-15 | U-1643 | |
| 10006924 | 2036-08-12 | U-1643 | |
| 10495650 | 2036-08-12 | U-1643 | |
| 9943526 | 2036-04-20 | U-1643 | |
| 10166242 | 2036-04-20 | U-1643 | |
| 10166243 | 2036-04-20 | U-1643 | |
| 10660904 | 2036-04-20 | U-1643 | |
| 10500216 | 2033-03-05 | U-1643 | |
| 10842801 | 2032-11-15 | U-1643 | |
| 8921348 | 2028-08-27 | U-1643 | |
ATC Codes
G: Genito urinary system and sex hormones
— G03: Sex hormones and modulators of the genital system
— G03X: Other sex hormones and modulators of the genital system in atc
— G03XB: Progesterone receptor modulators, sex hormones and modulators of the genital system
— G03XB01: Mifepristone
— G03XB51: Mifepristone, combinations
HCPCS
Code | Description |
|---|---|
| S0190 | Mifepristone, oral, 200 mg |
Clinical
Clinical Trials
214 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cushing syndrome | D003480 | EFO_0003099 | E24 | — | — | 3 | 1 | 2 | 6 |
| Adrenocortical hyperfunction | D000308 | EFO_1000797 | — | — | — | — | 1 | 1 | 2 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | 1 | — | 1 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 1 | 6 | — | — | 7 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | 1 | 6 | — | — | 7 |
| Pituitary acth hypersecretion | D047748 | EFO_1001110 | E24.0 | — | — | 4 | — | 2 | 6 |
| Psychotic disorders | D011618 | — | F20.81 | — | — | 6 | — | — | 6 |
| Depression | D003863 | — | F33.9 | — | — | 6 | — | — | 6 |
| Mental disorders | D001523 | EFO_0000677 | F91.9 | — | — | 6 | — | — | 6 |
| Syndrome | D013577 | — | — | — | — | 3 | — | 2 | 5 |
| Acth-secreting pituitary adenoma | D049913 | — | — | — | — | 2 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | — | — | — | 2 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | 1 | — | — | — | 2 |
| Weight gain | D015430 | — | — | 1 | 1 | — | — | — | 2 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 1 | — | — | — | 1 |
| Body weight | D001835 | EFO_0004338 | — | — | 1 | — | — | — | 1 |
| Adrenal insufficiency | D000309 | — | — | — | 1 | — | — | — | 1 |
| Wounds and injuries | D014947 | — | T14.8 | — | 1 | — | — | — | 1 |
| Lung neoplasms | D008175 | — | C34.90 | — | 1 | — | — | — | 1 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | 1 | — | — | — | 1 |
| Traumatic stress disorders | D040921 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 5 | — | — | — | — | 5 |
| Prostatic neoplasms | D011471 | — | C61 | 1 | — | — | — | — | 1 |
| Triple negative breast neoplasms | D064726 | — | — | 1 | — | — | — | — | 1 |
| Sarcoma | D012509 | — | — | 1 | — | — | — | — | 1 |
| Transitional cell carcinoma | D002295 | — | — | 1 | — | — | — | — | 1 |
| Ovarian epithelial carcinoma | D000077216 | — | — | 1 | — | — | — | — | 1 |
| Drug interactions | D004347 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Mifepristone |
| INN | mifepristone |
| Description | Mifepristone is a 3-oxo-Delta(4) steroid, an acetylenic compound and a tertiary amino compound. It has a role as an abortifacient, a contraceptive drug, a synthetic oral contraceptive and a hormone antagonist. It derives from a hydride of an estrane. |
| Classification | Small molecule |
| Drug class | steriodal compounds acting on progesterone receptors (excluding-gest- compounds); progesterone receptor antagonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C |
Identifiers
| PDB | — |
| CAS-ID | 84371-65-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1276308 |
| ChEBI ID | 50692 |
| PubChem CID | 55245 |
| DrugBank | DB00834 |
| UNII ID | 320T6RNW1F (ChemIDplus, GSRS) |
Target
Agency Approved
NR3C1
NR3C1
PGR
PGR
Organism
Homo sapiens
Gene name
NR3C1
Gene synonyms
GRL
NCBI Gene ID
Protein name
glucocorticoid receptor
Protein synonyms
Nuclear receptor subfamily 3 group C member 1, nuclear receptor subfamily 3 group C member 1 variant hGR-B(54), nuclear receptor subfamily 3 group C member 1 variant hGR-B(77), nuclear receptor subfamily 3 group C member 1 variant hGR-B(93), nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)
Uniprot ID
Mouse ortholog
Nr3c1 (14815)
glucocorticoid receptor (Q61629)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 13,211 documents
View more details
Safety
Black-box Warning
Black-box warning for: Korlym, Mifeprex, Mifepristone
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
7,436 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use